February 21, 2013
ABBOTT PARK, Ill., Feb. 21, 2013 – Abbott announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.
November 28, 2012
ABBOTT PARK, IL, Nov. 28, 2012 – Abbott and BioView, Ltd. have entered into an agreement in which BioView will develop automated digital imaging software for use with Abbott's molecular diagnostic test to detect rearrangements of the ALK gene in patients with advanced non-small cell lung cancer (NSCLC). The imaging software scans lung tissue specimens that have been tested for the ALK gene rearrangement with Abbott's fluorescence in situ hybridization (FISH) technology.
October 24, 2012
ABBOTT PARK, Ill., Oct. 24, 2012 — Abbott announced today that it will expand the current CE-IVD product labeling for its Vysis® ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with XALKORI (crizotinib), an oral first-in-class ALK inhibitor.
September 06, 2012
ABBOTT PARK, Ill., Sept. 6, 2012 — Abbott announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVaxTM), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.